GR3025655T3 - Determination of peptide motifs on mhc molecules. - Google Patents

Determination of peptide motifs on mhc molecules.

Info

Publication number
GR3025655T3
GR3025655T3 GR970403308T GR970403308T GR3025655T3 GR 3025655 T3 GR3025655 T3 GR 3025655T3 GR 970403308 T GR970403308 T GR 970403308T GR 970403308 T GR970403308 T GR 970403308T GR 3025655 T3 GR3025655 T3 GR 3025655T3
Authority
GR
Greece
Prior art keywords
peptide motifs
determination
mhc molecules
disclosed
mhc
Prior art date
Application number
GR970403308T
Other languages
English (en)
Inventor
Olaf Roetzschke
Kirsten Falk
Stefan Stevanovic
Guenther Jung
Hans-Georg Rammensee
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of GR3025655T3 publication Critical patent/GR3025655T3/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
GR970403308T 1992-11-13 1997-12-10 Determination of peptide motifs on mhc molecules. GR3025655T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4238416A DE4238416A1 (de) 1992-11-13 1992-11-13 Bestimmung von Peptidmotiven auf MHC-Molekülen
PCT/EP1993/003175 WO1994011738A1 (de) 1992-11-13 1993-11-12 Bestimmung von peptidmotiven auf mhc-molekülen

Publications (1)

Publication Number Publication Date
GR3025655T3 true GR3025655T3 (en) 1998-03-31

Family

ID=6472850

Family Applications (1)

Application Number Title Priority Date Filing Date
GR970403308T GR3025655T3 (en) 1992-11-13 1997-12-10 Determination of peptide motifs on mhc molecules.

Country Status (11)

Country Link
EP (1) EP0669001B1 (el)
JP (1) JPH07509319A (el)
KR (1) KR100194117B1 (el)
AT (1) ATE158082T1 (el)
AU (1) AU673212B2 (el)
CA (1) CA2147863C (el)
DE (2) DE4238416A1 (el)
DK (1) DK0669001T3 (el)
ES (1) ES2109658T3 (el)
GR (1) GR3025655T3 (el)
WO (1) WO1994011738A1 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
SG49008A1 (en) * 1993-03-05 1998-05-18 Cytel Corp Hla-a2.1 binding peptides and their uses
US5610013A (en) * 1993-07-22 1997-03-11 Ludwig Institute For Cancer Research Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors
US5648226A (en) * 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
US7025964B1 (en) 1996-11-13 2006-04-11 Meiji Dairies Corporation Peptide-based immunotherapeutic agent
EP1027073A2 (en) * 1996-11-19 2000-08-16 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
US6413517B1 (en) 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
EP2177534A3 (en) 1999-11-18 2010-07-14 Pharmexa Inc. Heteroclitic analogs of class i epitopes
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
DZ3332A1 (fr) 2000-03-31 2001-10-11 Purdue Research Foundation Methode de traitement a l'aide de conjugues ligand-immunogene
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
MXPA04005382A (es) 2001-11-07 2005-02-24 Mannkind Corp Vectores de expresion que codifican epitopes de antigenos asociados al objetivo y metodos para su diseno.
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
EP2226332A1 (en) 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
WO2015050259A1 (ja) * 2013-10-03 2015-04-09 大日本住友製薬株式会社 腫瘍抗原ペプチド
WO2020037046A1 (en) * 2018-08-14 2020-02-20 Board Of Regents, The University Of Texas System Single molecule sequencing peptides bound to the major histocompatibility complex

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365525B1 (en) * 1987-01-30 1995-08-09 The Board Of Trustees Of The Leland Stanford Junior University Lymphocyte inhibition by hla peptides
DE4143467C2 (de) * 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung

Also Published As

Publication number Publication date
EP0669001B1 (de) 1997-09-10
AU5465694A (en) 1994-06-08
WO1994011738A1 (de) 1994-05-26
CA2147863C (en) 2002-12-24
KR950704688A (ko) 1995-11-20
EP0669001A1 (de) 1995-08-30
ATE158082T1 (de) 1997-09-15
KR100194117B1 (ko) 1999-06-15
CA2147863A1 (en) 1994-05-26
DE4238416A1 (de) 1994-05-19
JPH07509319A (ja) 1995-10-12
ES2109658T3 (es) 1998-01-16
DE59307354D1 (de) 1997-10-16
DK0669001T3 (da) 1998-05-04
AU673212B2 (en) 1996-10-31

Similar Documents

Publication Publication Date Title
AU673212B2 (en) Determination of peptide motifs on MHC molecules
CA2103148A1 (en) Determination of motifs of peptides on mhc molecules
MY105224A (en) Catalysts for the polymerization of olefins.
NL300140I1 (nl) Galanthamine, of verbindingen die eraan analoog zijn, voor behandeling van de ziekte van Alzheimer.
GEP20033094B (en) Steroid Sulphatase Inhibitors
GB9503601D0 (en) Method of treatment and method of manufacture of medicament
EP0641819A3 (en) Process for the preparation of an organosilicon polymer.
GB9126725D0 (en) Process
FI891473A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 4-aryyli-4-piperidiinikarbinolien valmistamiseksi
EP0219082A3 (en) Process for preparing halogen-magnesium alanate, and its use
BG38637A3 (en) Method for preparing 2- exo- hydroxy- 7- oxabicyclo [2, 2, 1] heptanes
IL65597A (en) Preparation of 1alpha,24,25-trihydroxy-and 24,25-dihydroxy-cholesterol and certain novel intermediates used therein
ES2162078T3 (es) Compuestos terapeuticos.
NO903338L (no) Fremgangsmaate for mikrobiologisk fremstilling av l-carnitin.
DE68922507D1 (de) Verfahren zur Herstellung von beta-2',2'-Difluornukleosiden.
NZ228023A (en) 24(r)-scymnol; preparatory processes and pharmaceutical compositions
AU1966888A (en) Process for stabilizing mixtures based on halogenated polymers
ATE73136T1 (de) Verfahren zur herstellung von 6alpha, 9alphadifluor-11beta, 17alpha-dihydroxy-16alpha-methyl4-pregnen-3,20-dion und dessen derivate.
TW239124B (en) Process for the preparation of 2,4,5-tribromopyrrole-3-carbonitrile
FI873489A7 (fi) Menetelmä 4-androsteeni-3,17-dionin ja 1,4-androstadieeni-3,17-dionin valmistamiseksi.
FR2703994B1 (fr) Procédé de préparation de beta-lactames.
DE58906998D1 (de) Verfahren zur Herstellung von 4,5,6-Trichlorpyrimidin.
AU1568995A (en) Analogs of thymosin alpha1
UA41500A1 (uk) Спосіб позапічного оброблення сталі
UA11670A1 (uk) Засіб для укоріhеhhя череhків можевельhика віргіhського